Skip to main content

Table 5 Univariate analysis for first skeletal-related event

From: Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity

Variable RR (95% CI) pvalue
Age ≥ 50 years 0.94 (0.63, 1.40) 0.760
ECOG performance status    
   2 – 3 versus 0 – 1 1.81 (1.21, 2.72) 0.004
Hydroxyproline/Creatinine ratio (centered) 1.00 (0.97, 1.04) 0.921
Bone-specific alkaline phosphatase, U/L 1.01 (1.00, 1.01) 0.204
Estrogen-receptor status versus negative    
   Positive 0.56 (0.34, 0.92) 0.023
   Unknown 0.89 (0.58, 1.36) 0.580
Progesterone-receptor status versus negative    
   Positive 0.62 (0.38, 1.01) 0.053
   Unknown 0.78 (0.52, 1.16) 0.214
Sites of metastasis (yes versus no)    
   Bone as only metastatic site 0.84 (0.57, 1.24) 0.392
   Lung 1.32 (0.77, 2.29) 0.317
   Liver 1.26 (0.75, 2.13) 0.379
Time from diagnosis of bone metastases to study entry, years 1.00 (0.95, 1.04) 0.912
Time from cancer diagnosis to study entry, years 1.00 (0.96, 1.04) 0.947
Lesion characteristics and numbers    
   ≥ 3 osteolytic versus < 3 osteolytic 1.92 (1.29, 2.84) 0.001
   1 – 2 osteoblastic versus no osteoblastic 1.28 (0.82, 2.02) 0.282
   ≥ 3 osteoblastic versus no osteoblastic 0.39 (0.32, 0.50) < 0.001
   1 – 2 mixed versus no mixed 1.16 (0.64, 2.09) 0.624
   ≥ 3 mixed versus no mixed 1.26 (0.77, 2.06) 0.352
Prior fracture (yes versus no) 1.78 (1.12, 2.81) 0.014
Pain scores (centered) 1.29 (1.19, 1.40) < 0.001
Prior chemotherapy (yes versus no) 0.89 (0.32, 2.48) 0.816
≥ 2 prior hormonal therapies (yes versus no) 1.11 (0.75, 1.63) 0.605
Prior radiotherapy (yes versus no) 2.02 (1.35, 3.02) < 0.001
  1. Values in bold represent statistically significant correlations.
  2. RR = Relative risk, CI = Confidence interval, ECOG = Eastern Cooperative Oncology Group, U = Units.